Physician profile

Angelo Landriscina

Dermatology · New York, NY

NPI 1760836373

$149,458.09

in general payments reported to CMS, 2019-2025

5 companies · $59K in 2025

The $59K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).

See the full distribution for Dermatology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$99,947.50
Travel and Lodging$2,948.31
Food and Beverage$25.58

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Galderma Laboratories, L.P. $147,940.50 2020-2025
Celgene Corporation $1,311.35 2019
Pfizer INC. $124.74 2019
Abbvie INC. $55.92 2020
Solta Medical, A Division of Bausch Health US, LLC $25.58 2025

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Angelo Landriscina

$149,458.09

in general payments reported 2019-2025

Years
2019-2025
Top company
Galderma Laboratories, L.P.
Context
The $59K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).

https://glasscript.com/doctor/5697966/angelo-landriscina

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.